Mepolizumab 40 mg prefilled syringes have been approved by the USFDA for children aged 6–11 years old with severe eosinophilic asthma (SEA). Mepolizumab can now be administered by a child's healthcare practitioner or by a caregiver who has been educated by a healthcare professional at home. Mepolizumab Mepolizumab is the first monoclonal antibody in its class to target IL-5. It functions by inhibiting IL-5 from attaching to its receptor on the surface of eosinophils, resulting in decreased blood eosinophils and a return to normal levels.
Mepolizumab is produced as a prefilled syringe solution, a prefilled autoinjector, and a lyophilized powder in a vial that is reconstituted for injection for in-office usage. Mepolizumab can treat disorders caused by inflammation triggered by eosinophils. It has been licensed in the US, the EU, and over 25 additional markets as an add-on maintenance…
